CB-010

DRUG2 trials

Sponsors

Caribou Biosciences, Inc.

Conditions

B Cell LymphomaB Cell Non-Hodgkin's LymphomaLupusLupus ErythematosusLupus NephritisLymphomaLymphoma, Non-HodgkinNon Hodgkin Lymphoma

Phase 1

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

RecruitingNCT04637763

Caribou Biosciences, Inc.B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma, Lymphoma +4

Start: 2021-05-26End: 2025-09-30Target: 72Updated: 2025-03-24

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)

WithdrawnNCT06752876

Caribou Biosciences, Inc.Lupus, Lupus Erythematosus, Lupus Nephritis +1

Start: 2027-12-31End: 2029-04-30Updated: 2025-09-19

Related Papers

A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial.

Journal of Clinical Oncology2024-06-0111 citations

A First-in-Human Phase 1, Multicenter, Open-Label Study of CB-010, a Next-Generation CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)

Blood2022-11-1517 citations

P1455: FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY)

HemaSphere2022-06-0115 citations